| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | leptomycin B | CTRPv2 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | Nutlin-3 | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.9 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |